OrbiMed Advisors
http://www.orbimed.com/OrbiMed is the world's largest healthcare-dedicated investment firm, with approximately $5 billion in assets under management. The firm was stated in 1989 with a vision to invest across the spectrum of healthcare companies: from private start-ups to large multinational companies.
View Older Stories View More Recent Stories
-
Form SC 13D/A Xtant Medical Holdings, Filed by: ORBIMED ADVISORS LLC
-
PlacementTracker Publishes 2017 PIPE and Private Placement Markets League Tables
-
Form SC 13G Kala Pharmaceuticals, Filed by: ORBIMED ADVISORS LLC
-
Form SC 13D/A PIERIS PHARMACEUTICALS, Filed by: ORBIMED ADVISORS LLC
-
Neurogastrx, Inc. Raises $45M Series A To Bring Lead GI Candidate Through Proof Of Concept
-
ORIC Has Appointed Rich Heyman, PhD as Acting Chief Executive Officer and Leonard Reyno, MD as Chief Medical Officer
-
Pionyr Immunotherapeutics Completes $62 Million Series B Financing to Advance Antibody-based Therapeutics Targeting the Tumor Microenvironment
-
OrbiMed Founder, Samuel D. Isaly, to Step Down
-
PMV Pharma Appoints Winston Kung as COO & CFO
-
Goldfinch Bio Appoints Anthony Johnson, M.D., President and Chief Executive Officer, and Michael Broxson, Chief Business and Operating Officer
-
Form SC 13D scPharmaceuticals Inc. Filed by: ORBIMED ADVISORS LLC
-
Form SC 13D Arsanis, Inc. Filed by: ORBIMED ADVISORS LLC
-
Form SC 13D/A Loxo Oncology, Inc. Filed by: ORBIMED ADVISORS LLC
-
Form 13F-HR ORBIMED ADVISORS LLC For: Sep 30
-
Alpine Immune Sciences Reports Corporate Update and Third Quarter 2017 Financial Results
-
Natera Reports Third Quarter 2017 Financial Results
-
Form SC 13D/A Intellia Therapeutics, Filed by: ORBIMED ADVISORS LLC
-
Inspire Medical Systems Ranks #2 on Cleveland Clinic’s List of the Top 10 Medical Innovations for 2018
-
Form SC 13D/A ViewRay, Inc. Filed by: ORBIMED ADVISORS LLC
-
ORIC Pharmaceuticals Announces First Subject Dosed in Phase 1 Clinical Study of Novel GR Antagonist with Planned Development for Oncology
-
Form SC 13D RHYTHM PHARMACEUTICALS, Filed by: ORBIMED ADVISORS LLC
-
Gemini Therapeutics Announces $42.5 Million Series A Financing to Develop Precision Therapeutics in Ophthalmology and Rare Genetic Diseases
-
PlacementTracker Publishes Q3 2017 Private Placement Market League Tables
-
Form SC 13D/A Roka BioScience, Inc. Filed by: ORBIMED ADVISORS LLC
-
Form SC 13D/A Roka BioScience, Inc. Filed by: ORBIMED ADVISORS LLC
-
Brookline Capital Markets Announces a Major Expansion of Its Healthcare Investment Banking Services, Equity Research Department and Team
-
Form SC 13D/A Roka BioScience, Inc. Filed by: ORBIMED ADVISORS LLC
-
KaNDy Therapeutics Launched to Advance a Breakthrough Treatment in Women's Health
-
ProMIS Neurosciences Independent Director Anthony J. Giovinazzo Recognized with Inaugural Bloom Burton Award for Innovation in Canadian Healthcare
-
Inspire Medical Systems' Inspire Therapy for Reducing Obstructive Sleep Apnea Demonstrates Long-term Safety and Sustained Benefit Following 5 Years of Treatment
-
Sonendo® Announces Growth Investment from General Atlantic
-
Form SC 13D SYNLOGIC, INC. Filed by: ORBIMED ADVISORS LLC
-
Form SC 13D/A Clementia Pharmaceutical Filed by: ORBIMED ADVISORS LLC
-
Form SC 13D/A Roka BioScience, Inc. Filed by: ORBIMED ADVISORS LLC
-
Avitide, Inc., Receives ISO 9001:2015 Certification for Its Affinity Resin Manufacturing Facility
-
Form SC 13D/A SELECTA BIOSCIENCES INC Filed by: ORBIMED ADVISORS LLC
-
Form 13F-HR ORBIMED ADVISORS LLC For: Jun 30
-
Form SC 13D Clementia Pharmaceutical Filed by: ORBIMED ADVISORS LLC
-
Form SC 13D/A ViewRay, Inc. Filed by: ORBIMED ADVISORS LLC
-
Natera Reports Second Quarter 2017 Financial Results
-
Form SC 13D ALPINE IMMUNE SCIENCES, Filed by: ORBIMED ADVISORS LLC
-
Intellia Therapeutics Announces Second Quarter 2017 Financial Results
-
Cyrus Biotechnology Announces $8M Financing to Expand Computational Drug Discovery Software Platform
-
Alpine Immune Sciences, Inc. Completes Merger with Nivalis Therapeutics, Inc.
-
Intellia Therapeutics (NTLA) Appoints Moncef Slaoui and Frank Verweil to Board
-
Intellia Therapeutics Names Moncef Slaoui, Ph.D. and Frank Verwiel, M.D. to Its Board of Directors and Establishes a Science and Technology Committee
-
Form SC 13D/A OTONOMY, INC. Filed by: ORBIMED ADVISORS LLC
-
Sangamo Biosciences (SGMO) Names Roger Jeffs & Joseph Zakrzewski to Board
-
Sangamo Therapeutics Appoints Roger Jeffs, Ph.D. and Joseph S. Zakrzewski to its Board of Directors
-
Nabriva (NBRV) Appoints Carrie Bourdow and Colin Broom to the Board

